We report the successful angioplasty of an acute arterial narrowing after suture-mediated closure (SMC) of a femoral arterial puncture. A 75-year-old woman underwent a cerebral arteriogram via a right common femoral artery puncture. The arteriotomy site was closed with a SMC device. Four days after placement the patient complained of pain in her right calf after walking. An arteriogram 7 days after SMC showed a severe focal stenosis at the origin of the superficial femoral artery involving the presumed puncture site. The lesion was successfully treated with balloon angioplasty. The patient at 6 months was asymptomatic.
A 75-year-old woman underwent a cerebral angiogram from a right common femoral artery puncture for evaluation of transient ischemic attacks. The right common femoral artery was accessed with a #19 gauge singlewall needle and a 5 Fr sheath placed. After the procedure, a femoral arteriogram was performed and the arteriotomy site was closed with a SMC device (Closer, Perclose, Menlo Park, CA, USA) (Fig. 1A ) without immediate complication. The evening after the cerebral arteriogram the patient complained of pain in her right groin radiating down her leg. The patient was afebrile and her white blood cell count was normal. Her distal pulses were palpable with no preprocedural change. There was no evidence of a hematoma or bruit at the puncture site. The patient was discharged the day after the arteriogram, and the groin pain resolved 3 days after the procedure.
One week later the patient presented with acute right calf claudication (approximately 100 yards) and was re-admitted to the hospital. The right ankle brachial index (ABI) was 0.36 (preprocedural ABI ϭ 0.93). A right lower extremity arteriogram was performed from the left femoral approach, which showed a tight stenosis at the origin of the right superficial femoral artery (Fig. 1B) . After discussion with the referring vascular surgeon, a decision was made to treat the lesion with balloon angioplasty. A 5.5 Fr contralateral introducer (Balkin, Cook, Bloomington, IN, USA) was advanced into the right external iliac artery. The proximal superficial femoral artery stenosis was negotiated with a 4 Fr hydrophilic-coated Cobra catheter and a 0.035 inch angled hydrophilic-coated torque wire (Medi-tech, Watertown, MA, USA) using road-mapping. Angioplasty was performed with a 4 mm diameter ϫ 20 mm long RxVIA/TRAC 14 monorail balloon catheter over a 0.014 inch Sparta Core wire (Guidant, Temecula, CA, USA) to 10 atm (147 psi, balloon diameter 4.08 mm at 10 atm). The lesion was further dilated with a 5 mm diameter ϫ 20 mm long RxVIA/TRAC 14 monorail balloon catheter. The waist was eliminated after inflating the balloon to 15 atm (220.5 psi, balloon diameter ϭ 5.37 mm at 15 atm). The final arteriogram revealed no residual stenosis and excellent blood flow in the superficial femoral artery was noted (Fig. 1C) .
The following day after the balloon angioplasty, ankle pressure measurement revealed an ABI of 0.88. The patient had no claudication symptoms. The patient has remained asymptomatic for 6 months after angioplasty.
Discussion
Arterial narrowing related to the use of a SMC device is rare. To our knowledge there has been no published report on the use of balloon angioplasty in the management of puncture site stenosis complicating the use of a closure device.
The three commonly used SMC devices are the Closer, Prostar XL, and Prostar plus (Perclose, Menlo Park, CA, USA). The Closer is the current 6 Fr platform, which replaced the Techstar 6 Fr system and is indicated for use in 5 and 6 Fr sheath access sites. The device is inserted over a standard guidewire until pulsatile flow is present through a marker lumen. Footplates are deployed inside the vessel and the device is retracted until flow ceases in the marker lumen. Two needles are then deployed from outside the vessel into the footplates and the suture (3-0 polyester) is captured and pulled through the arterial wall and subsequently through the device. The sutures are then retrieved and a clinch knot is tied using a knottying device. The delivery system is removed and the knot is pulled down to the arteriotomy with tension on the rail suture. A knot pusher is then used to push the knot securely against the arterial wall.
The polyester surgical sutures with the Closer system elicit a minimal acute inflammatory reaction in tissues, followed by grad-ual encapsulation of the suture by fibrous connective tissue [5] . Polyester surgical sutures are not absorbed, nor is any significant change in tensile strength known to occur in vivo.
It is our belief that the inflammatory reaction may have contributed to the stenosis in our patient. The patient did complain of pain at the puncture site, which may have been related to the inflammatory reaction; however, there was no erythema or warmth at the puncture site. Some authors have advocated excluding balloon angioplasty in patients with inflammatory arteritis with serologic evidence of active disease (elevated erythrocyte sedimentation rate or C-reactive protein), although the effect of disease activity on the outcome of angioplasty is unknown [6] . However, Dong et al. [7] reported an 86% clinical success 6 months after renal angioplasty in patients with Takayasu's arteritis, even though 45% of the patients had an elevated erythrocyte sedimentation rate at the time of dilatation. In our case the patient did respond to balloon angioplasty even though there may have been underlying inflammation at the SMC site.
Thrombus formation at the SMC site may be another potential cause for the stenosis. This could occur from the trauma caused to the endothelium from the puncture or deployment of the SMC device. Furthermore, the suture material acting as a foreign body could also promote thrombus formation.
We were initially reluctant to perform balloon dilatation on the arteriotomy site 1 week after the initial puncture, because of the theoretical risk of rupturing the artery or creating a pseudoaneurysm. However, after further discussion with the vascular surgeon we proceeded with balloon angioplasty. The region was dilated only to 5 mm to avoid potential complications because of the recent arteriotomy. At 6 months there was no evidence of a pseudoaneurysm by clinical examination.
SMC devices were studied in the STAND I and STAND II Trials [8] . STAND I evaluated the 6 Fr Techstar device in 200 patients following catheterization with 5 Fr, 6 Fr, or 6.5 Fr sheaths. Major complications occurred in 2 patients (1%), 1 patient underwent surgical repair for a pseudoaneurysm, and 1 patient developed local site infection requiring outpatient antibiotics. Minor complications occurred in 3 patients (1.5%); 1 patient developed a hematoma Ͼ6 cm, and 2 patients developed a small pseudoaneurysm requiring no further therapy. Postprocedural ultrasound studies were obtained in the first 73 patients per protocol: 2 patients had a small pseudoaneurysm as described above, and no patient had intra-arterial thrombus or luminal narrowing at the closure site.
The STAND II Trial was a multicenter study of 515 patients randomized to SMC versus traditional compression. A sheath size Ն8 Fr was used in 57% of patients. Major complications occurred in 2.4% of the suture closure group and 1.1% of the compression group (p ϭ NS). The median time to hemostasis (19 vs 243 min, p Ͻ 0.01) and time to ambulation (3.9 vs 14.8 h, p Ͻ 0.01) were significantly shorter for SMC.
The Closer European (CE) Trial was a multicenter registry of 200 patients which examined the safety and effectiveness of the Closer 6 Fr SMC system. The study was designed to detect differences in the observed incidence of major complications at 30 days relative to two pre-specified historical control groups of patients undergoing diagnostic procedures. Major complications occurred in no patients. Minor complications occurred in 5 patients (2.5%; 3 patients (1.5%) developed a hematoma Ͼ 6 cm, 1 patient (0.5%) developed vessel narrowing at the insertion site which was successful treated by balloon angioplasty, and 1 patient (0.5%) developed an arteriovenous fistula. The results have not been published in a journal, but are available on the Perclose website [9] .
In October 1999, the FDA Center for Devices and Radiological Health issued a warning statement and recommendations related to the use of vascular hemostasis devices [10] . Table 1 summarizes the FDA recommendations. The FDA's recommendations were followed during deployment of the device in our patient. A single-wall anterior puncture was utilized. The postprocedural management instructions and ambulation recommendations were followed. The patient was not on glycoprotein IIB/IIIA inhibitors or anticoagulated.
It is our belief the anteroposterior (AP) femoral arteriogram before the arterial access closure shows a low puncture of the common femoral artery just above the origins of the superficial and deep femoral arteries (Fig. 1A) . The femoral bifurcation is not in profile. An ipsilateral oblique projection would show the true puncture site to be lower than on the AP arteriogram involving the origin of the superficial femoral artery. This additionally likely contributed to the stenosis, since the manufacture recommends puncturing the middle portion of the common femoral artery. Since this complication we have performed an ipsilateral oblique and AP arteriogram on all patients before placing a SMC device. If the puncture site is near the femoral bifurcation we do not use a SMC device.
In summary, stenoses caused by placement of the 6 Fr SMC device can be successfully treated with balloon angioplasty, eliminating the need for surgery. Making sure the arteriotomy site is over the middle of the common femoral artery may limit this complication. Table 1 . FDA recommendations to minimize injuries involving closure devices 1. Carefully follow the manufacturer's warnings, precautions, and instructions 2. Do not use these devices to treat patients with suspected punctures of the posterior wall 3. Monitor the groin site to minimize the occurrence of complications 4. Weigh the risks of bleeding at the puncture site against the benefits of using the closure device when treating patients with bleeding disorders or patients medicated with glycoprotein IIb/IIIa inhibitors 5. Observe postprocedural patient management instructions and ambulation recommendations for the closure device
